

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Angus McDougall Caithness
<b>Date of last notice</b>	17 December 2020

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Banquo Consulting Pty Ltd - Mr Caithness is a director
<b>Date of change</b>	12 March 2021
<b>No. of securities held prior to change</b>	<u>Direct</u> 177,491 Ordinary shares 3,500,000 Options exercisable at 30 cents, expiring 28 February 2022 500,000 Class C Performance Rights 500,000 Class D Performance Rights 500,000 Class E Performance Rights 115,516 Director Share Rights  <u>Indirect</u> 5,500,000 Ordinary shares
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	(a) 500,000 (b) 71,782 (c) 115,516
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>(a) Nil consideration. Issued upon conversion of Performance Rights:-          - 166,666 Class C Performance Rights          - 166,667 Class D Performance Rights          - 166,667 Class E Performance Rights</p> <p>(b) Deemed consideration of \$39,420, being forgiven salary for the period 1 November 2020 to 28 February 2021. Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 2A dated 12 March 2021.</p> <p>(c) Nil consideration. Issued on exercise of Director Share Rights, which were issued on 17 December 2020</p>
<p><b>No. of securities held after change</b></p>	<p><u>Direct</u>          864,789 Ordinary shares          3,500,000 Options exercisable at 30 cents, expiring 28 February 2022</p> <p>333,334 Class C Performance Rights          333,333 Class D Performance Rights          333,333 Class E Performance Rights</p> <p><u>Indirect</u>          5,500,000 Ordinary shares</p>
<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>(a) Issue of fully paid ordinary shares upon satisfaction of Performance Rights milestones, being:-          - Class C Performance Rights – upon the Company's 20-day VWAP equalling or exceeding \$0.55 before 4 February 2023          - Class D Performance Rights – upon the Company's 20-day VWAP equalling or exceeding \$0.65 before 4 February 2023          - Class E Performance Rights - upon the Company's 20-day VWAP equalling or exceeding \$0.75 before 4 February 2023</p> <p>(b) Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed above and previously approved by shareholders</p> <p>(c) Issued on exercise of Director Share Rights as detailed above</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Fleta Jennifer Solomon
<b>Date of last notice</b>	17 December 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	12 March 2021
<b>No. of securities held prior to change</b>	19,600,000 fully paid ordinary shares  500,000 Class C Performance Rights 500,000 Class D Performance Rights 500,000 Class E Performance Rights  114,716 Director Share Rights
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	(a) 500,000 (b) 40,723 (c) 114,716

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>(a) Nil consideration. Issued upon conversion of Performance Rights:-</p> <ul style="list-style-type: none"> <li>- 166,666 Class C Performance Rights</li> <li>- 166,667 Class D Performance Rights</li> <li>- 166,667 Class E Performance Rights</li> </ul> <p>(b) Deemed consideration of \$22,363 being forgiven salary for the period 1 November 2020 to 28 February 2021. Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 2A dated 12 March 2021.</p> <p>(c) Nil consideration. Issued on exercise of Director Share Rights, which were issued on 17 December 2020</p>
<b>No. of securities held after change</b>	<p>20,255,439 fully paid ordinary shares</p> <p>333,334 Class C Performance Rights  333,333 Class D Performance Rights  333,333 Class E Performance Rights</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>(a) Issue of fully paid ordinary shares upon satisfaction of Performance Rights milestones, being:-</p> <ul style="list-style-type: none"> <li>- Class C Performance Rights – upon the Company's 20-day VWAP equalling or exceeding \$0.55 before 4 February 2023</li> <li>- Class D Performance Rights – upon the Company's 20-day VWAP equalling or exceeding \$0.65 before 4 February 2023</li> <li>- Class E Performance Rights - upon the Company's 20-day VWAP equalling or exceeding \$0.75 before 4 February 2023</li> </ul> <p>(b) Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed above and previously approved by shareholders</p> <p>(c) Issued on exercise of Director Share Rights as detailed above</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael David Lynch-Bell
<b>Date of last notice</b>	17 December 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	12 March 2021
<b>No. of securities held prior to change</b>	600,000 Ordinary shares 300,000 Retention Share Rights 150,917 Director Share Rights
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	(a) 82,826 (b) 150,917
<b>Number disposed</b>	Nil

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>(a) Deemed consideration of \$45,485, being forgiven salary for the period 1 November 2020 to 28 February 2021. Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 2A dated 12 March 2021.</p> <p>(b) Nil consideration. Issued on exercise of Director Share Rights, which were issued on 17 December 2020</p>
<b>No. of securities held after change</b>	<p>833,743 Ordinary shares  300,000 Retention Share Rights</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>(a) Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed above and previously approved by shareholders</p> <p>(b) Issued on exercise of Director Share Rights as detailed above</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Neale William Fong
<b>Date of last notice</b>	17 December 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director  Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee
<b>Date of change</b>	12 March 2021
<b>No. of securities held prior to change</b>	Riverpalm Pty Ltd <NW Fong Family Trust> 250,000 Ordinary shares  Dr Neale Fong <Damblock Trust> 675,000 Ordinary shares 150,000 Retention Share Rights 75,458 Director Share Rights
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	41,413

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Deemed consideration of \$22,742, being forgiven salary for the period 1 November 2020 to 28 February 2021. Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 2A dated 12 March 2021.
<b>No. of securities held after change</b>	Riverpalm Pty Ltd <NW Fong Family Trust> 250,000 Ordinary shares  Dr Neale Fong <Damblock Trust> 716,413 Ordinary shares 150,000 Retention Share Rights 75,458 Director Share Rights
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed above and previously approved by shareholders

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.